Azitra (AZTR) Operating Income (2022 - 2026)
Azitra's (AZTR) quarterly Operating Income came in at -$3.9 million in Q1 2026, down 26.89% YoY from -$5.4 million in Q1 2025, and down 73.56% on a QoQ basis from -$2.3 million in Q4 2025.
Azitra (AZTR) Operating Income (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Operating Income data on file, last reported at -$3.9 million in Q1 2026.
- Quarterly Operating Income fell 26.89% year-over-year to -$3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.8 million (down 6.44% YoY) and the FY2025 annual result came in at -$11.0 million, changed 0.17% from the prior year.
- Operating Income eased to -$3.9 million in Q1 2026, from -$2.3 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$1.4 million in Q2 2023 to a low of -$3.9 million in Q1 2026.
- A 5-year average of -$2.5 million and a median of -$2.6 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income soared 31.64% — and 2024, when it plunged 89.99%.
- Tracing AZTR's Operating Income over 5 years: stood at -$2.7 million in 2022, then gained by 8.44% to -$2.5 million in 2023, then advanced by 1.47% to -$2.4 million in 2024, then grew by 6.88% to -$2.3 million in 2025, then tumbled by 73.56% to -$3.9 million in 2026.
- The last three Operating Income figures came in at -$3.9 million (Q1 2026), -$2.3 million (Q4 2025), and -$2.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | Azitra | 2.55 Mn | 2.55 Mn | - | -3.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.42 Mn |
| Mar 31, 2026 | -3.93 Mn |
| Dec 31, 2025 | -2.27 Mn |
| Sep 30, 2025 | -2.77 Mn |
| Jun 30, 2025 | -2.87 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Dec 31, 2024 | -2.43 Mn |
| Sep 30, 2024 | -2.93 Mn |
| Jun 30, 2024 | -2.66 Mn |
| Mar 31, 2024 | -2.96 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -1.99 Mn |
| Jun 30, 2023 | -1.43 Mn |
| Mar 31, 2023 | -1.56 Mn |
| Dec 31, 2022 | -2.70 Mn |
| Sep 30, 2022 | -2.37 Mn |
| Jun 30, 2022 | -2.09 Mn |